D 1927

Drug Profile

D 1927

Latest Information Update: 11 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech R&D
  • Class Antineoplastics
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Age-related macular degeneration; Cancer; Rheumatoid arthritis

Most Recent Events

  • 11 Sep 2002 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 11 Sep 2002 Discontinued - Preclinical for Age-related macular degeneration in United Kingdom (unspecified route)
  • 20 Aug 2001 Preclinical development for Age-related macular degeneration in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top